Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drotrecogin Alfa (Activated) Dose and Duration in Severe Sepsis
NCT00386425Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2006
- Primary completion
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of drotrecogin alfa in sepsis (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean Change in Protein C Levels From Day 1 to Day 7. Started Nov 2006; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT00386425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386425.